Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Denikitug |
| Trade Name | |
| Synonyms | GS1811|GS 1811|JTX 1811|JTX1811|JTX-1811|GS-1811 |
| Drug Descriptions |
Denikitug (GS-1811) is a monoclonal antibody targeted against CCR8, which potentially induces antibody-dependent cell mediated cytotoxicity (ADCC) and depletion of tumor-infiltrating regulatory T cells (Tregs) (Cancer Res 2020;80(16 Suppl):Abstract nr 4532). |
| DrugClasses | CCR8 Antibody 13 |
| CAS Registry Number | 2865822-82-6 |
| NCIT ID | C206899 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + Denikitug + Trifluridine-tipiracil hydrochloride | Bevacizumab Denikitug Trifluridine-tipiracil hydrochloride | 0 | 1 |
| Denikitug | Denikitug | 0 | 2 |
| Denikitug + Nivolumab | Denikitug Nivolumab | 0 | 1 |
| Denikitug + Pembrolizumab | Denikitug Pembrolizumab | 0 | 1 |